Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

healthcare professional

- PMLiVE

One-carbon Therapeutics collaborates with Tempus in cancer treatment

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

Healthcare Research Worldwide

- PMLiVE

Smarter Learning and Better Outcomes: How AI Can Provide an Advantage in Medical Education

See how AI-powered patient avatars allow physicians to test complex diagnoses and treatment plans in a simulated environment.

Impetus Digital

- PMLiVE

New Webinar: 2026 Engagement Strategies For Modern Pharma

Turn interaction into intelligence! Don’t miss this chance to lead the industry with our free pharma-exclusive webinar!

Impetus Digital

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

Medicus Pharma completes patient enrolment for basal cell carcinoma trial

Interim results have shown over 60% clinical clearance in patients treated with SkinJect

- PMLiVE

Researchers at University of Geneva develop test platform for cancer treatments

The new platform could speed up testing while reducing the need for animal models

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

- PMLiVE

Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

Uniphar

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links